Evidence map›Paper›PMID 27902461›Full record

ArticleOncotarget2017

Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes.

Danielle M Karyadi, Milan S Geybels, Eric Karlins, Brennan Decker, Laura McIntosh, Amy Hutchinson, Suzanne Kolb, Shannon K McDonnell, Belynda Hicks, Sumit Middha and 9 more

Abstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact.Transactions of the American Clinical and Climatological Association · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Danielle M KaryadiNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Milan S GeybelsDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Eric KarlinsNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Brennan DeckerNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Laura McIntoshDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Amy HutchinsonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Suzanne KolbDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Shannon K McDonnellDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Belynda HicksDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sumit MiddhaDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Liesel M FitzGeraldMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Melissa S DeRyckeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Meredith YeagerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Daniel J SchaidDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Stephen N ThibodeauDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Janet L StanfordDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Elaine A OstranderNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

Funding

Prostate Cancer Susceptibility: The ICPCG StudyU01CA089600 · NCI · MAYO CLINIC ROCHESTER · PI THIBODEAU, STEPHEN NORMAN · 2002 to 2016
$27.3M
Finding Genes for Human Prostate CancerZIAHG200325 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI OSTRANDER, ELAINE · 2009 to 2021
$17.7M
GENETIC EPIDEMIOLOGY OF PROSTATE CANCERR01CA080122 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 1999 to 2008
$3.8M
NSAIDS and Other Medications in Prostate Cancer EtiologyR01CA092579 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 2001 to 2005
$3.2M
PROSTATE CANCER IN RELATION TO VASECTOMYR01CA056678 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 1993 to 1997
–
NCI NIH HHS R01 CA056678NCI NIH HHS R01 CA080122NCI NIH HHS R01 CA092579NCI NIH HHS U01 CA089600NHGRI NIH HHS HHSN268200782096C
6 · The paper itself

Abstract

Prostate cancer (PCa) susceptibility is defined by a continuum from rare, high-penetrance to common, low-penetrance alleles. Research to date has concentrated on identification of variants at the ends of that continuum. Taking an alternate approach, we focused on the important but elusive class of low-frequency, moderately penetrant variants by performing disease model-based variant filtering of whole exome sequence data from 75 hereditary PCa families. Analysis of 341 candidate risk variants identified nine variants significantly associated with increased PCa risk in a population-based, case-control study of 2,495 men. In an independent nested case-control study of 7,121 men, there was risk association evidence for TANGO2 p.Ser17Ter and the established HOXB13 p.Gly84Glu variant. Meta-analysis combining the case-control studies identified two additional variants suggestively associated with risk, OR5H14 p.Met59Val and CHAD p.Ala342Asp. The TANGO2 and HOXB13 variants co-occurred in cases more often than expected by chance and never in controls. Finally, TANGO2 p.Ser17Ter was associated with aggressive disease in both case-control studies separately. Our analyses identified three new PCa susceptibility alleles in the TANGO2, OR5H14 and CHAD genes that not only segregate in multiple high-risk families but are also of importance in altering disease risk for men from the general population. This is the first successful study to utilize sequencing in high-risk families for the express purpose of identifying low-frequency, moderately penetrant PCa risk mutations.

Indexed as

AgedAged, 80 and overCase-Control StudiesExome SequencingGenetic Predisposition to DiseaseHumansMaleMiddle AgedProstatic NeoplasmsRisk Factorscancer susceptibilitycase-control associationhigh-risk familiesprostate cancerwhole exome sequencing

Identifiers

PMID27902461
PMCPMC5341753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.